Idenix Pharmaceuticals, Inc.
) recently announced that the company has decided to discontinue
its clinical development program for IDX184.
IDX184 is a nucleotide polymerase inhibitor in phase IIb
development for treating patients suffering from hepatitis C
virus (HCV) infection. Idenix also decided not to continue the
development of IDX19368, an HCV nucleotide polymerase inhibitor.
We note that Idenix had filed an investigational new drug
application (IND) for IDX19368 but had not initiated patient
We note that in Aug 2012, the US Food and Drug Administration
(FDA) put IDX184 on partial clinical hold and IDX19368 on
clinical hold due to safety concerns after serious
cardiac-related adverse events were found to be associated with
Bristol-Myers Squibb Company's
) BMS-986094 (formerly known as INX-189).
BRISTOL-MYERS (BMY): Free Stock Analysis
IDENIX PHARMA (IDIX): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
PEREGRINE PHARM (PPHM): Free Stock Analysis
To read this article on Zacks.com click here.
BMS-986094 is also a nucleotide polymerase inhibitor, which was
being developed for the treatment of HCV. Bristol-Myers decided
to discontinue BMS-986094 due to safety issues.
Subsequently, Idenix submitted the requested cardiac safety data
for IDX184 to the FDA in Dec 2012. Idenix has found no
evidence of severe cardiac findings till now.
However, the FDA informed Idenix that IDX184 and IDX19368
programs would remain on clinical hold. Hence, the company has
decided to discontinue the development of these programs.
Nevertheless, Idenix is completing IND-enabling studies for a
uridine nucleotide analog, a sub-class of nucleotide polymerase
inhibitors distinct from IDX184, IDX19368 and BMS-986094. Idenix
expects to file an IND for this candidate in the first half of
Idenix is also developing an all-oral direct-acting antiviral
(DAA) HCV combination therapy incorporating IDX719, which is a
pan-genotypic NS5A inhibitor for HCV. This is being done in
collaboration with Janssen Pharmaceuticals, Inc., a US-based arm
Johnson & Johnson's
) global pharmaceuticals segment.
Idenix currently carries a Zacks Rank #2 (Buy). A biopharma stock
that currently looks more attractive is
Peregrine Pharmaceuticals, Inc
). It carries a Zacks Rank #1 (Strong Buy).